Alzheimer's disease: β‐amyloid plaque formation in human brain
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Although the precise cause of Alzheimer's disease is not known, the β‐amyloid peptide chains of 40–42 amino acids are suspected to contribute to the disease. The β‐amyloid precursor protein is found on many types of cell membranes, and the action of secretases (β and γ) on this precursor protein normally releases the β‐amyloids at a high rate into the plasma and the cerebrospinal fluid. However, the concentrations of the β‐amyloids in the plasma and the spinal fluid vary considerably between laboratories. The β‐amyloids adsorb in the nanomolar concentration range to receptors on neuronal and glial cells. The β‐amyloids are internalized, become folded in the β‐folded or β‐pleated shape, and then stack on each other to form long fibrils and aggregates known as plaques. The β‐amyloids likely act as monomers, dimers, or multimers on cell membranes to interfere with neurotransmission and memory before the plaques build up. Treatment strategies include inhibitors of β‐ and γ‐secretase, as well as drugs and physiological compounds to prevent aggregation of the amyloids. Several immune approaches and a cholesterol‐lowering strategy are also being tested to remove the β‐amyloids. Synapse, 2011. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“…enzymes found in tissues, it has been possible to isolate another protease that has all the known characteristics of b-secretase (namely, b-site amyloid-precursor proteincleaving enzyme; Vassar et al., 1999), an enzyme that can be conveniently labeled by a radioactive drug (Iben et al., 2008).”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“tures (Lambert et al., 1998); approximately 0.”
BackgroundInfluentialInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“In conclusion, it is recognized that there are at least seven genes that are associated with Alzheimer’s disease (Hollingworth et al., 2011; Naj et al., 2011).”
BackgroundNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“In conclusion, it is recognized that there are at least seven genes that are associated with Alzheimer’s disease (Hollingworth et al., 2011; Naj et al., 2011).”
BackgroundAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citationRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 8×
“These monoclonal antibodies include bapineuzumab (AAB-001), solanezumab (LY-2062430), ponezumab (PF-04360365), GSK-933776, R-1450 (RO-4909832), and MABT-5102A (Mangialasche et al., 2010; Panza et al., 2011).”
InfluentialSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“…concentrations of approximately 100 nM of b-amyloid-42 oligomers (but not monomers) selectively bind to synaptic junctions of specific neurons (De Felice et al., 2007, 2009; Lacor et al., 2004), inducing the loss of insulin receptors and N-methyl-D-aspartate receptors (Decker et al., 2010; De…”
BackgroundEarly-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 2×
“…approximately 100 nM of b-amyloid-42 oligomers (but not monomers) selectively bind to synaptic junctions of specific neurons (De Felice et al., 2007, 2009; Lacor et al., 2004), inducing the loss of insulin receptors and N-methyl-D-aspartate receptors (Decker et al., 2010; De Felice et al., 2009).”
BackgroundGeneration of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.
Busciglio, J., Gabuzda, D. H., Matsudaira, P., & Yankner, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2092 · Cited by 569 · cited 2×
“VC 2011 WILEY-LISS, INC. cells) secrete b-amyloid (Busciglio et al., 1993).”
Yang, D.-S., Stavrides, P., Mohan, P. S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S. D., Wesson, D., Bandyopadhyay, U., Jiang, Y., et al. (2011) · Brain · doi:10.1093/brain/awq341 · Cited by 429
Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering
Sandberg, A., Luheshi, L. M., Söllvander, S., Pereira de Barros, T., Macao, B., Knowles, T. P. J., Biverstål, H., Lendel, C., Ekholm-Petterson, F., Dubnovitsky, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001740107 · Cited by 358 · cited 3×
“propensity to pair up with each other to form a dimer or a trimer or an aggregate of many more b-amyloid molecules to form amyloid plaques (Fig. 3; Chiti and Dobson, 2006; Sandberg et al., 2010; Soreghan et al., 1994).”
BackgroundAttenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors
Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E., Vinters, H. V., & Tontonoz, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701096104 · Cited by 358 · cited 1×
“…this receptor (e.g., TO-901317 and GW 3965) have been tested to reduce cholesterol and amyloid aggregates (Burns et al., 2006; Loane et al., 2011; Patel and Forman, 2004; Riddell et al., 2007; Suon et al., 2010; Vanmierio et al., 2009; see also Canepa et al., in press and Zelcer et al., 2007).”
BackgroundPlatelets Are the Primary Source of Amyloid β-Peptide in Human Blood
Chen, M., Inestrosa, N. C., Ross, G. S., & Fernandez, H. L. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2103 · Cited by 320
Jan, A., Gokce, O., Luthi-Carter, R., & Lashuel, H. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803159200 · Cited by 291
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., et al. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.01.011 · Cited by 244 · cited 1×
“…this receptor (e.g., TO-901317 and GW 3965) have been tested to reduce cholesterol and amyloid aggregates (Burns et al., 2006; Loane et al., 2011; Patel and Forman, 2004; Riddell et al., 2007; Suon et al., 2010; Vanmierio et al., 2009; see also Canepa et al., in press and Zelcer et al., 2007).”
BackgroundAll Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228 · cited 1×
“Although there are many risk factors leading to schizophrenia, including genes, there is a final common mechanism of dopamine supersensitivity (Seeman, 2011).”
BackgroundSelf-citationFitz, N. F., Cronican, A., Pham, T., Fogg, A., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1051-10.2010 · Cited by 175
Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
Caetano, F. A., Beraldo, F. H., Hajj, G. N. M., Guimaraes, A. L., Jürgensen, S., Wasilewska-Sampaio, A. P., Hirata, P. H. F., Souza, I., Machado, C. F., Wong, D. Y.-L., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07225.x · Cited by 74 · cited 1×
“Moreover, there is suggestive evidence that the prion protein may serve as a receptor for b-amyloid (Caetano et al., 2011; Gunther and Strittmatter, 2010).”
BackgroundBien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., & Huang, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018381108 · Cited by 71 · cited 1×
“In fact, purified ApoE4 protein, especially when associated with fat, retains b-amyloid-42 in the body, reducing the removal of b-amyloid-42 (Bien-Ly et al., 2011; Sharman et al., 2010).”
BackgroundSharman, M. J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I. J., Lim, W. L. F., Singh, S., Wenk, M. R., Ghiso, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100141 · Cited by 54 · cited 1×
“In fact, purified ApoE4 protein, especially when associated with fat, retains b-amyloid-42 in the body, reducing the removal of b-amyloid-42 (Bien-Ly et al., 2011; Sharman et al., 2010).”
BackgroundLemmens, M. A. M., Sierksma, A. S. R., Rutten, B. P. F., Dennissen, F., Steinbusch, H. W. M., Lucassen, P. J., & Schmitz, C. (2011) · Brain Structure and Function · doi:10.1007/s00429-011-0305-1 · Cited by 37
Cited by
ER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments
Ajoolabady, A., Lindholm, D., Ren, J., & Pratico, D. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05153-5 · Cited by 261
Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease
Gerakis, Y., & Hetz, C. (2018) · The FEBS Journal · doi:10.1111/febs.14332 · Cited by 226
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Bourgade, K., Garneau, H., Giroux, G., Le Page, A. Y., Bocti, C., Dupuis, G., Frost, E. H., & Fülöp, T. (2015) · Biogerontology · doi:10.1007/s10522-014-9538-8 · Cited by 208
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
Metadata
- Authors
- Seeman, P., & Seeman, N.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2011-10-11
- Volume
- 65
- Issue
- 12
- Pages
- 1289-1297
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2137910690
- Cited by
- 97
- References
- 27
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.